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Simple Summary: This is a safety and efficacy analysis from a very large dataset of patients affected
by localized prostate cancer having received radiotherapy with or without concomitant androgen
deprivation therapy in twelve academic and non-academic Italian Institutions. The aim of this
retrospective "real life" study was to provide additional data on clinical presentation, diagnostic
workup, radiation therapy management and toxicity as collected within the framework of POP
III. Though the usual limitations for a retrospective analysis apply, it nevertheless may expand the
current knowledge in this area showing the progress of radiation therapy techniques and clinical
outcomes in the period between 2004 and 2011 after a significant period of follow up.
Abstract: Background and purpose: Two previous “Patterns Of Practice” surveys (POP I and POP
II), including more than 4000 patients affected by prostate cancer treated with radical external beam
radiotherapy (EBRT) between 1980 and 2003, established a “benchmark” Italian data source for
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prostate cancer radiotherapy. This report (POP III) updates the previous studies. Methods: Data on
clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011
were collected and compared with POP II and, when feasible, also with POP I. This report provides
data on clinical presentation, diagnostic workup, radiation therapy management, and toxicity as
collected within the framework of POP III. Results: More than 50% of POP III patients were classified
as low or intermediate risk using D’Amico risk categories as in POP II; 46% were classified as ISUP
grade group 1. CT scan, bone scan, and endorectal ultrasound were less frequently prescribed. Dose-
escalated radiotherapy (RT), intensity modulated radiotherapy (IMRT), image guided radiotherapy
(IGRT), and hypofractionated RT were more frequently offered during the study period. Treatment
was commonly well tolerated. Acute toxicity improved compared to the previous series; late toxicity
was influenced by prescribed dose and treatment technique. Five-year overall survival, biochemical
relapse free survival (BRFS), and disease specific survival were similar to those of the previous series
(POP II). BRFS was better in intermediate- and high-risk patients treated with ≥ 76 Gy. Conclusions:
This report highlights the improvements in radiotherapy planning and dose delivery among Italian
Centers in the 2004–2011 period. Dose-escalated treatments resulted in better biochemical control
with a reduction in acute toxicity and higher but acceptable late toxicity, as not yet comprehensively
associated with IMRT/IGRT. CTV-PTV margins >8 mm were associated with increased toxicity, again
suggesting that IGRT—allowing for tighter margins—would reduce toxicity for dose escalated RT.
These conclusions confirm the data obtained from randomized controlled studies.
Keywords: Pattern Of Practice; prostate cancer; radiotherapy
1. Introduction
Prostate Cancer (PCa) is the second most frequently diagnosed tumor in the male
population worldwide [1]. In Italy, it represents approximately 19% of all tumors diagnosed
in men aged 50 and older, excluding skin cancers [2].
Radiation therapy (RT) is a very effective treatment modality for PCa. The introduc-
tion of new treatment planning and dose delivery technology further strengthened its role
as a radical and postoperative treatment, allowing the implementation of dose escalation
protocols and hypofractionated radiotherapy (HypoRT) with acceptable rectal and geni-
tourinary toxicity. The clinical impact of image-guided radiotherapy (IGRT) techniques
has already been tested in randomized trials, highlighting an improved tumor control and
decreased toxicity, resulting in a favorable therapeutic index [3,4]. In 2002 and 2013, two
different Italian studies were published assessing the patterns of practice (POP) of PCa
patients in Italy [5,6]. The current study was performed by the Uro-Oncology Study Group
of the Italian Society of Radiotherapy and Clinical Oncology (AIRO) to assess the diffusion
of new technologies such as IMRT/VMAT and IGRT and their impact on clinical outcome
and toxicity in the 2004–2011 period.
2. Materials and Methods
In an iterative process, the Uro-Oncology Study Group of AIRO defined the shared
database items for the 2004–2011 observation period, taking into account those previ-
ously investigated in the first two surveys. To simplify the description of the results, the
previously published series have been labeled POP I (1995–1998 period) and POP II (1999–
2003 period), while the current series is referred to as POP III. Five academic and seven
non-academic hospital-based centers located in the central and northern Italian regions
participated in the current study; among them, four participated in POPI and POPII, four
participated only in POPII, and the remaining four only in POPIII. A web-based database
was created to collect patient, tumor, diagnostic, treatment, and technical features.
Data on 2525 prostate cancer patients treated consecutively with radical EBRT in
association or not with androgen deprivation therapy (ADT) from 2004 to 2011 were
collected. All patients were treated according to the individual center protocols, all aligned
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with the available national and international guidelines. Patients were followed at each
center for a period of at least 5 years in an out-patient clinic, every 3–6 months during
the first 2–3 years and every 6–12 months thereafter. The retrospective data collection
procedure was approved by the Ethical Committee of the coordinating center (Modena,
practice n◦ 231/13) and subsequently by those of each participating center. Follow-up
information was retrieved from patient clinical records (and follow-up visits, when needed
to update charts in living patients). Acute and late GI and GU toxicity rates (scored by the
RTOG toxicity scale) [7] were recorded at the different follow up intervals, and the most
severe toxicity experienced by the patients was reported for the purpose of this analysis.
Because this is a retrospective data collection based on a large multi-institutional
database, it was not possible to retrieve all data related to some of the analyzed variables.
In the Results section, all missing data are, however, clearly identified. Not all the database
items were present in all three series. To better elucidate the progressive diffusion of
the technical innovations, the study period was also divided into two consecutive four-
year periods; the number of patients treated was almost equally distributed between the
2004–2007 quadriennium (1246, 49%) and the subsequent one (2008–2011, 1279, 51%).
Statistical Analysis
A descriptive analysis of POP III was performed and data were compared to those
from POP I and POP II. To find significant differences for some categorical variables, the
Chi-squared test was used, while for continuous (scale) variables the T-test and the one-way
ANOVA were used. Cancer-specific death, death by any cause and biochemical failure by
ASTRO criteria [8] (the same used in POPI and POPII), calculated from the end of RT, were
analyzed with the Kaplan–Meier method (KM) to obtain five-year disease-specific (DSS),
overall survival (OS), and biochemical relapse-free survival (BRFS) rates for the whole
series. KM was also used to evaluate patients’ rate of late side effects, and the log-rank test
was used to compare the risk of biochemical failure between D’Amico risk groups. The
statistical analysis was performed by using SPSS vv 24©. Graphs were created with Graph
Pad prism 6©.
3. Results
3.1. Patients’ Clinical Features
Median age was 72 years (range, 46–88), median follow-up was 6 years (range 0–13).
More than 50% (1495, 59%) of patients presented with low or intermediate D’Amico risk
disease, in line with the POP II (52%) cohort, while 1016 patients (40%) presented with high
risk disease. Mean PSA at diagnosis was 14.14 ng/mL ± 19.03 SD. Cases with PSA values
> 20 ng/mL dropped from 32% (POP I) to 27% (POP II) to 15% (POP III).
It was possible to calculate the ISUP group for most POP II and POP III patients [9].
1152 POP III patients (46%) were classified as Group 1, 548 (22%) as Group 2, 254 (10%)
as Group 3, 356 (14%) as Group 4, and 188 (7%) as Group 5. While only relatively small
differences were observed in the distribution of the ISUP group, a Gleason score between
2–5 was reported in only 6% of the POP III cohort, as opposed to 27% of the POP II cases
(p < 0.0001); this observation parallels the 11% increase in the proportion of patients with
Gleason sum ≥ 7 in the POP III series.
More than 60% of the POP III patients showed clinically evident disease being classi-
fied as cT2 or cT3 using the TNM [10]. Regarding nodal status, only 2% of the cases had
positive nodes. Patient’ features are reported in Table 1.
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Table 1. Clinical features of the patients enrolled in the three subsequent surveys.






Median age (range, yr) 70 (range, 28–89) 71 (range, 46–86) 72 (range, 46–88)
T stage
1 99 (10) 597 (20) 866 (34)
2 577 (57) 1732 (58) 1177 (47)
3 284 (28) 621 (21) 450 (18)
4 17 (2) 29 (1) 11 (<1)
Unknown 28 (3) 5 (>1) 21 (<1)
N stage
N+ 32 (3) 75 (3) 42 (2)
N0 504 (50) 2502 (83) 1761 (70)
Nx 469 (47) 424 (14) 722 (28)
Grade group (ISUP)
Group 1 (Gleason score ≤ 6) Not evaluable 1380 (46) 1152 (46)
Group 2 (Gleason score 3 + 4 = 7) Not evaluable 460 (16) 548 (22)
Group 3 (Gleason score 4 + 3 = 7) Not evaluable 279 (9) 254 (10)
Group 4 (Gleason score 8) Not evaluable 314 (10) 356 (14)
Group 5 (Gleason scores 9–10) Not evaluable 153 (5) 188 (7)
Unknown Not evaluable 409 (14) 27 (1)
Patients with Gleason score 2–5
Not evaluable 814 (27) 163 (6)
Gleason sum
2–6 606 (61) 1676 (56) 1152 (46)
7 142 (14) 777 (26) 805 (32)
8–10 114 (11) 506 (17) 543 (22)
Unknown 143 (14) 42 (1) 25 (1)
Baseline PSA (ng/mL)
<1 0 (0) 0 (0) 24 (<1)
1–10 345 (34) 1292 (43) 1481 (59)
10.1–20 277 (28) 886 (30) 617 (24)
>20 326 (32) 810 (27) 395 (15)
Unknown 57 (6) 13 (<1) 8 (<1)
Median baseline PSA (ng/mL) 13 12 8.2
D’Amico category risk
Low risk 34 (3) 516 (17) 739 (29)
Intermediate risk 342 (33) 1057 (35) 756 (30)
High Risk 432 (43) 1356 (46) 1016 (40)
Not assessable 197 (21) 72 (2) 14 (<1)
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3.2. Diagnostic Workup
Significant differences were found between POP II and POP III regarding diagnostic
staging procedures before treatment (Table 2). Abdominal/pelvic CT scans (73% vs. 53%)
(p = 0.001) as well as transrectal ultrasound (87% vs. 68%) (p = 0.001) and bone scans (84%
vs. 53%) (p = 0.001) were used in fewer patients in POP III than in POP II. No statistically
significant difference was found for the use of magnetic resonance imaging. Only a small
number of POP III patients (2%) was staged with choline PET; this procedure was not used
at all among POP I and POP II patients.
















No 395 (39) 798 (27) 1186 (47)
p < 0.001
Yes 610 (61) 2203 (73) 1339 (53)
Abdominal/pelvic magnetic resonance
No 867 (86) 2808 (94) 2335 (92)
p = 0.171
Yes 138 (14) 193 (6) 190 (8)
Transrectal ultrasound
No 254 (25) 385 (13) 809 (32)
p < 0.001
Yes 751 (75) 2616 (87) 1716 (68)
Magnetic resonance with endorectal coil
No 911 (91) 2714 (90) 2251 (89)
p = 0.114
Yes 94 (9) 287 (10) 274 (11)
Bone scan
No 86 (9) 471 (16) 1181 (47)
p < 0.001
Yes 919 (91) 2530 (84) 1344 (53)
Staging lymphadenectomy
No 928 (92) 2945 (98) Not evaluated
\\
Yes 77 (8) 56 (2) Not evaluated
Choline PET
No Not evaluated Not evaluated 2476 (98)
\\
Yes Not evaluated Not evaluated 49 (2)
TURP
No Not evaluated 2741 (91) 2299 (91)
\\Yes Not evaluated 259 (9) 215 (8)
Unknown Not evaluated 1 (<1) 11 (<1)
3.3. Treatment Features
Prescription dose (Figure 1) in patients who underwent conventionally fractionated
RT (1.8–2 Gray [Gy]/fraction) clearly increased when compared to the previous series, as
1136 patients of POP III were given a total dose ≥ 76 Gy (45% vs. 9% in POP II) (p = 0.001),
and the mean dose to the prostate (74.1 Gy) was significantly higher (one-way ANOVA,
p < 0.0001) than in POP II (71.6 Gy) and POP I (69 Gy). Less than 1% of patients treated
with conventional fractionation received doses < 70 Gy (Table 3).
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Table 3. Therapeutic procedures adopted in the three subsequent surveys.





2525 Patients (No., %)
Dose to prostate
<70 Gy s.f 315 (31) 218 (7) 20 (<1)
70–75 Gy s.f. 689 (69) 2531 (84) 1257 (50)
≥76 Gy s.f. 1 (<1) 252 (9) 1136 (45)
≤70 hypo 2.5–3.1 Gy Dmean to prostate EqD2 (α/β = 1.5): 78 Gy * Not performed Not performed 47 (2)
>70 hypo 2.2–2.35 Gy Dmean to prostate EqD2 (α/β = 1.5): 79 Gy * Not performed Not performed 20 (<1)
>70 hypo 2.7 Gy Dmean to prostate EqD2 (α/β = 1.5): 84.2 Gy * Not performed Not performed 40 (2)
Unknown 5 (<1)
Dmean to prostate (Gy) **
Conventional fractionation 69 71.6 74.1
EqD2 (α/β = 1.5) 74.5
Treated volume
No pelvic irradiation 784 (78) 2497 (83) 2416 (95)
Pelvic irradiation 221 (22) 504 (17) 107 (4)
Unknown 2 (<1)
Beam energy, MV
≤10 62 (6) 174 (6) 1479 (59)
10–18 421 (42) 2026 (68) 613 (24)
≥18 522 (52) 252 (8) 283 (11)
Unknown - 549 (18) 150 (6)
Conformal techniques
2D-RT 593 (59) 725 (24) -
Static 3D-CRT 412 (41) 2174 (72) 1953 (77)
Dynamic 3D-CRT Not performed 95 (3) 4 (<1)
IMRT Not performed 7 (<1) 568 (22)
IGRT
No All All 2188 (87)




Unknown All All 153 (5)
Concomitant hormone therapy
No 201 (20) 644 (22) 581 (23)
Yes 804 (80) 2226 (74) 1911 (76)
Unknown - 131 (4) 33 (1)
sf = standard fraction (1.8–2 Gy); hypo = hypofractionated regimens; * D mean = mean prostate dose in the subgroup; ** All patients.
All patients were treated with conformal RT; 1957 patients (78%) were treated with
three-dimensional conformal RT while 568 (22%) underwent IMRT.
IGRT also started to be available and was used in 337 patients (13%) recruited in the
POP III study.
The use of HypoRT is reported for the first time in the current series; 20 patients (<1%)
underwent a moderately HypoRT regimen (dose per fraction 2.2–2.3 Gy), 47 patients (2%)
were treated with higher dose per fraction (2.5–3.1 Gy), but with a total dose < 70 Gy, and
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40 patients (2%) underwent a shorter HypoRT schedule (dose per fraction 2.7 Gy) with a
total dose higher than 70 Gy.
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Figure 1. Dose delivered to prostate: POP I (1995–1998), POP II (1999–2003), POP III (2004–2011).
Hypo: hypofractionation, s.f.: standard fractionation.
As widely accepted [11,12], we considered a prostate tumor α/β ratio of 1.5 to obtain
normalized equivalent dose in 2-Gy fractions (EqD2) using the linear quadratic model.
The mean equivalent dose (EqD2) to the prostate overall was 74.5 Gy (hypofractionated
regimens included).
Mean dose (EqD2) to the prostate with HypoRT was 80.7 Gy, significantly higher
(one-way ANOVA, p <0.0001) than the conventionally fractionated schedules.
HypoRT was predominantly delivered with IGRT (86% vs. 10% of conventional
regimens) and IMRT (97% vs. 19% of conventional regimens) techniques.
Mean ose (EqD2) to the prostate in IMRT treated patients was 77 Gy, significantly
higher than in patients treated with 3D-CRT (74 Gy, t-test p = 0.04). Patients treated with
IGRT techniques received a mean dose (EqD2) to the prostate significantly higher (76 Gy)
than those treated without IGRT (74 Gy, t-test p < 0.0001).
Almost all patients (2416, 95%) in the current series underwent treatment to the
prostate and/or seminal vesicles, while prophylactic pelvic irradiation was delivered only
to 107 patients (4%). Median overall treatment tim was 54 days (SD ± 10). The photon
beam energy mainly used was ≤10 MV (1479, 59%). More than 90% of the patients were
treated in supine position with filled bladder and empty rectum. Isotropic CTV to PTV
expansion was used in more than 50% of the patients. When non-isotropic expansion was
performed, the posterior margin was reduced.
Most patients (70%) were reated with a TV-PTV margin ≥ 8 mm. A smaller CTV-
PTV margin was used when IGRT was given (70% vs. 19%, p < 0.0001); about 50% of the
patients treated with the IMRT technique had CTV-PTV margins >8 mm (Figure 2).
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Figure 2. Percentage of treatment plans with CTV-PTV margin ≥ or <8 mm in IMRT vs. No IMRT
treatments and IGRT vs. No IGRT treatme t .
A larger CTV-PTV margin (≥8 mm) was used more frequently among patients who
received a total dose (EQD2) ≤ 74 Gy than in those receiving >74 Gy (82% vs. 64%,
p < 0.0001).
By dividing the series into two consecutive time periods (2004–2007 and 2008–2011),
it clearly emerges that th most modern techniques (IMRT and IGRT) w re used more
frequently during the second quadriennium and allowed an increase in the dose delivered
as well as a reduction in the CTV-PTV margins (Table 4).
Concomitant androgen deprivation therapy (ADT) was administered to the vast
majority of the POP III patients (76%), similar to what was previously reported for POP I
and POP II. D ta about the type f ADT was not available for 635 patients (25%). Of the
remaining 1890, 578 (30.6 ) had total androgen blockade, 592 (31.3%) were treated with
LH-RH analogues, and 720 (38%) were treated with a peripheral antiandrogen alone. The
mean duration of ADT was 18 months.
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Table 4. Techniques, doses, CTV-PTV margins and toxicity in the first and second half of the accrual period; (*) = data
unknown for 153 cases. Pts = patients.
Treatment Features and Toxicity Period p
2004–2007 (1246 Patients, 49%) 2008–2011 (1279 Patients, 51%)
Pts treated with IMRT (%) 7% 38% p < 0.001
Pts treated with IGRT (%) 7% 19% p < 0.001
Pts treated with EqD2 ≥ 78 Gy (%) 22% 28% p < 0.001
Mean dose (EqD2) (±SD) Gy 74 Gy (± 3.6) 75 Gy (± 3.5) p < 0.001
CTV-PTV margin < 8 mm (%) (*) 15% 38% p < 0.001
Hypofractionation (%) 1% 7% p < 0.001
Acute GI (≥G2) toxicity (%) 15% 8% p < 0.001
Acute GU (≥G2) toxicity (%) 16% 14% p = NS
Late GI (≥G2) toxicity (%) 13% 13% p = NS
Late GU (≥G2) toxicity (%) 14% 8% p < 0.001
3.4. Acute Toxicity
Acute genito-urinary (GU) and gastrointestinal (GI) toxicity data were available for
almost all patients (missing data less than 1%). The treatment was generally well tolerated
because most patients experienced no or mild, clinically insignificant toxicity.
Grade 2 and 3 acute GU toxicity was reported in 343 patients (13%) and 30 patients
(1.2%), respectively, while grade 4 GU acute toxicity was reported in only 3 patients.
No grade 4 acute GI toxicity was reported; G2 acute GI toxicity was observed in
260 patients (10%), while only 22 patients (<1%) experienced G3 toxicity.
Comparing the crude acute toxicity rate of the current series with that of POP II, there
is a significantly (p < 0.0001) lower frequency of G2 cases in favor of the recent cohort,
while data were similar for both G3-G4 GI and GU toxicity (Figure 3).
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did not impact on the occurrence of both GU and GI acute toxicity (every grade); notably,
however, no G4 GU toxicity was reported in IGRT treated patients as opposed to 3 G4
events in the non-IGRT group.
Patients treated with a CTV-PTV margin ≥ 8 mm experienced a higher incidence of
acute GU toxicity (every grade, 66% vs. 60%, p < 0.01), whereas no significant impact on GI
toxicity was demonstrated.
Dosimetric data were available for more than 50% of the patients. Among them the
volume of rectum receiving 25% of the prescribed dose (V25r) and the dose at 50% of the
rectal volume (D50r) were significantly greater in patients experiencing acute GI toxicity
(every grade) (t-test, p < 0.001). Dose at 50% of the bladder volume (D50b) was significantly
higher in patients experiencing acute GU toxicity (every grade, t-test, p < 0.001).
Counterintuitively, patients treated with a total dose (EQD2) ≤ 74 Gy experienced a
higher incidence of GU (≥G2 grade) acute side effects than those who received >74 Gy
(59% vs. 41% p < 0.001); a similar result was found for GI (every grade) toxicity (51% vs.
27%, p < 0.0001).
Comparing the crude rates of acute toxicity in the two consecutive four-year periods
of the study, a clear relationship seems to emerge between an increase in treatments with
IMRT, IGRT, CTV-PTV margins ≤ 8 mm in the more recent quadriennium and a significant
reduction in acute GI toxicity incidence (Table 4). In addition, a non-significant reduction
in acute GU toxicity was observed in the study years 2008–2011; of note, in this period, a
significant increase in the fraction of patients treated with doses in excess of 78 Gy (EqD2)
and in the mean EqD2 dose has been observed (Table 4).
3.5. Late Toxicity
Late toxicity data were available for nearly 70% (1708) of the patients.
Cumulative probability of five-year late toxicity (GU, GI, every grade) was 30%.
Cumulative probability of five-year late GU and GI toxicity ≥ G2 was 12% and 15%,
respectively.
Late G2 and G3 GI toxicity was observed in 194 (7.7%) and 29 (1.1%) patients, respec-
tively; only 1 patient had G4 toxicity.
Late G2, G3, and G4 GU toxicity was registered respectively in 164 (7.7%), 13 (0.5%),
and 6 (0.2%) patients.
Not unexpectedly (because the average doses in POP III patients were higher than in
POP II) the crude rates of G2 GI and G2 GU late toxicities were higher for POP III patients
than in the previous series, while the percentage of patients who developed G3-G4 GI and
GU toxicity was similar among the three series (Figure 4).
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No significant impact of IMRT and IGRT (considered as dichotomous variables:
yes/no) on both GI and GU late toxicity was observed.
Patients treated with a CTV-PTV margin ≥8 mm experienced a higher incidence of
both late GI toxicity (every grade) (35% vs. 26%, chi-squared p < 0.0001), and late GU (≥G2)
(12% vs. 9%, chi-squared p = 0.02).
A dosimetric evaluation on available data was also performed for late toxicity; V25r,
D50r were significantly higher in patients who experienced late GI toxicity (every grade;
t-test, p < 0.001). None of the available dosimetric data was instead related to an increase in
GU late toxicity.
As described for acute toxicity, patients treated with a total dose (EQD2) ≤ 74 Gy
experienced a higher incidence of GU late toxicity (every grade) than those who received
>74 Gy (39% vs. 24%, chi-squared p < 0.001); a similar result was found for GI late toxicity
(every grade) (38% vs. 19%, chi-squared p < 0.0001).
As for acute toxicity, we compared the crude rates of late GU and GI toxicity (≥G2)
between the 2004–2007 and 2008–2011 study periods; no significant difference was found
for GI toxicity, while there was a significant decrease of GU toxicity in the more recent
period (Table 4). As already noted, in this period, a significant increase in the fraction of
patients treated with IGRT, IMRT, CTV-PTV margins ≤ 8 mm, doses in excess of 78 Gy
(EqD2), and in the mean EqD2 dose has been observed.
3.6. Overall Survival (OS) and Biochemical Relapse-Free Survival (BRFS)
Five year OS for the entire current series was 88%, equal to that reported for POP II
(88%) and higher than that reported for POP I (77%). Five-year DSS was 97% as opposed to
96% for POP II and 86% for POP I. Five-year BRFS (ASTRO definition) was 86%, in line with
POP II data (88%); data were not available for POP I. As expected, considering D’Amico risk
classification, five-year BRFS was 96%, 88%, and 78% for low, intermediate, and high risk
patients, respectively (log-rank, p < 0.0001). Intermediate and high risk patients (D’Amico
classification) treated with a total dose (EqD2) ≥ 76Gy enjoyed an increased five-year BRFS
(Figure 5) (95% vs. 86% for intermediate risk patients—84% vs. 76% for high risk patients,
log-rank, p < 0.0001)
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4. Discussion
Surgery and RT can both be considered standard treatments for localized PCa [13–16].
In Italy, however, surgery still remains the most frequently used therapeutic approach for
localized malignancies, especially for younger patients and those without relevant comor-
bidities [17]. From a radiation oncologists’ perspective, recent technological innovations
and the results of dose escalation studies [18–22] have led to a significant change in PCa
treatment. The Uro-Oncology Study Group of the Italian Association of Radiotherapy
and Clinical Oncology (AIRO) has been committed for years to collect a large number of
consecutive cases to allow the evaluation of the clinical impact of RT planning and delivery
advance on PCa patients. This effort led to the publication of the previous “Pattern Of
Practice” (POP) studies [5,6]. The present analysis addresses the 2004–2011 period; main
features of this period were the increasing adoption of hypofractionated schedules and
image guided radiation therapy.
While acknowledging the retrospective nature of our analysis and the different related
biases, some interesting information can be extracted. RT is confirmed as the preferred
choice in older patients, as demonstrated by the median age of patients included in the
present study (72 years, range 46–88). Almost 60% of patients had low or intermediate risk
PCa (D’Amico classification); notably, 1152 patients (46%) had a Gleason score 2 through
6, with a lower percentage of Gleason score 2–5 in POPIII compared the POP II series
(Table 1), which is likely a consequence of one of the major changes between the two
revisions of 2005 [23] and 2014 [24] of the grading consensus of the International Society
of Urologic Pathology (ISUP); the 2014 revision recommended that Scores 2–5 should no
longer be assessed on needle biopsies. This finding parallels the observed reduction in the
number of patients with pre-RT PSA values in excess of 20 ng/mL and the 11% increase in
those diagnosed with Gleason sum ≥7 in the POP III series, and points to a more accurate
selection of patients.
More than 50% of the patients were staged using abdominal CT scan with i.v. contrast,
bone scan, and endorectal ultrasound, in agreement with current guidelines [13–16], which
do not recommend the use of these diagnostic procedures in low risk group patients while
they can be performed in intermediate risk ones. The percentage observed is therefore
reasonable in our population, mostly represented by intermediate risk (30%) and high-risk
patients (40%), as some patients with intermediate risk cancer did not actually undergo
these procedures. On the other hand, endorectal and/or abdomino-pelvic magnetic reso-
nance imaging (MRI) was used in a very low number of patients. These findings would
likely be different nowadays, in view of the national and international guidelines’ recom-
mendation to implement the use of multiparametric MRI (mpMRI) before biopsy in daily
routine [13–16].
Doses to the prostate were significantly higher in comparison with POP II (Figure 1).
These data seem to be clearly influenced by dose escalation studies published since
2002 [18–22], which showed a clinical benefit for doses >70 Gy in terms of disease control.
For the first time, a small number of patients (107, 5%) was treated using moderate hypofrac-
tionation, confirming the increasing role of this strategy, particularly during the second half
of the study period; this trend was subsequently confirmed with the publication of relevant
positive studies with long term results [25–28]. Ninety-five percent of patients were treated
only to prostate ± seminal vesicles, thus confirming the trend towards the omission of
upfront prophylactic pelvic irradiation already observed in the POP II study, although
several patients with high-risk disease (about 40%) were included in both series. These
data reflect the lack of clear evidence for a clinical benefit of prophylactic pelvic irradiation
(PPI), even in the setting of high-risk patients. An ongoing multicenter study (PROEPI)
promoted by the AIRO Uro-Oncology Study Group will likely result in additional insight
in this scenario; given also that data from a randomized Phase III clinical trial favoring the
use of PPI in high and very high risk patients have been recently published [29].
Almost a quarter of the patients were treated with IMRT, while only a smaller fraction
of them (13%) was treated with IGRT. The photon beam energy mainly used was ≤10 MV
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(1479 cases, 59%); this finding confirmed the conclusion of the previous study that photon
beams between 10–18 MV were progressively abandoned, paralleling the increasing use
of IMRT.
Overall, the treatment was well tolerated, as the majority of patients experienced
only mild to moderate toxicities. In comparison to POP II, patients in the current series
showed better tolerance to RT treatment with a lower crude rate of acute toxicity ≥ grade
2. Reported grade 4 acute urinary toxicity remained as low in POP III as it was in POP II
(Figure 3). When analyzing the crude maximum late toxicity rates, most patients experi-
enced mild toxicity (grade 2), while only 7 patients experienced grade 4 toxicity (6 patients
GU and 1 GI, respectively) (Figure 4). Unexpectedly, patients treated with a total dose
(EqD2) ≤ 74 Gy developed a higher incidence of acute and late toxicity, the likely reasons
being the larger CTV-PTV margins used in this cohort in absence of IGRT.
Toxicity outcomes in our population are comparable with those reported in the con-
temporary literature. The review published by Ohri et al. [30] on nearly 12,000 PCa patients
treated with different RT doses (median dose 72 Gy) and techniques found a median rate
of late toxicity ≥ G2 of 15% and 17% for GI and GU events, respectively. On the other hand,
median rate of late toxicity ≥ G3 was only 2% and 3%, respectively. In accordance with a
plethora of previous data [19,21,31–33], also in this comparison of consecutive series, an
increase in the prescription dose seems to be slightly but consistently associated with an
increased toxicity.
In our series, no substantial reduction in the incidence of acute and late toxicity was
documented in patients treated with IMRT, probably due to the relatively small number
of patients treated with this technique and to the absence of a simultaneous homogenous
reduction of the CTV-PTV margins while increasing the dose among them.
This issue is still highly debated in the scientific community, so that in the NCCN
guidelines [13] the real impact of IMRT does not seem to be completely elucidated, while
the use of IGRT is recommended. From the available literature, IMRT seems to reduce
the rate of gastrointestinal toxicity, as confirmed in several studies [34–36]. More recently
Barelkowsky et al. [37] reported acute G2 and 3 GU toxicity in 39.8% and 1.1% of patients,
respectively, acute G2 and 3 GI toxicity in 12.5% and 0%, late G2 and 3 GU toxicity in 19.3%
and 4.5%, and late G2 and 3 GI toxicity in 4.5% and 1.1%. All patients were treated by IGRT
with Tomotherapy in a radical setting and no toxicity >G3 was observed. Additionally
Detti et al. [38] recently published a retrospective analysis on 394 patients treated with
radical high-dose EBRT (mean total dose 79 Gy, standard fractionation) for localized PCa
using IMRT with daily IGRT. The authors reported a low toxicity profile, with 51.8% G2
GU acute side effects and only 2 cases (0.5%) of G3 GU toxicity and no acute G3 GI toxicity.
Late toxicity rate was very low, with only 1 patient (0.2%) who developed G3 GU toxicity.
The authors concluded that IGRT should be mandatory for the treatment of PCa when high
dose EBRT is used. Results of the randomized IGIM trial (www.igimtrial.unimore.it), which
recently completed accrual, might further corroborate this recommendation. Considering
the data of the three retrospective series (POP I, POP II, POP III), the cumulative incidence
of late toxicity (at five years) reported for POP II [6] (24.8%) was lower than that reported
for POPI [5] (31–37%), while in POP III there was an increase (30%). This trend could be
explained by the fact that in the transition from POP I to POP II the dose prescription had
not yet changed and remained almost similar among the two series, while conformational
techniques were introduced in the daily practice. In POP III, on the other hand, a significant
dose escalation with better outcomes in terms of BRFS was achieved without a simultaneous
adjustment of the treatment techniques, especially in terms of a reduction in CTV-PTV
margins, at least in the first half of the study period (Table 4).
5. Conclusions
This longitudinal comparison of prostate RT practice patterns reported for a national
observational cohort provides a clear summary of the changes in recruitment, diagnosis,
adopted treatment techniques, prevalent dose prescriptions, and toxicity profile in the
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different time periods. Changes in histopathological assessment and staging procedures
that might have caused stage migration have also been observed. The data further confirm
that an increasing use of conformal techniques with IMRT and IGRT allowed the increase of
prescription doses consistently up to >70 Gy. PCa radiation therapy evolved simultaneously
during the study period towards an increasing use of hypofractionation, reduced CTV-PTV
margins, IMRT, and IGRT techniques, showing favorable results in terms of disease control
and treatment tolerance.
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